docetaxel,rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'docetaxel', 'triton3']
after also does a wonderful job presenting triton3 trial: rucaparib prolonged rpfs vs (docetaxel or 2nd nht) in pts after prior nht, os data immature. key ae: fatigue/asthenia (no mds) #gu23 what is the future of rucaparib? 
Oncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine